PMID: 29490321Mar 1, 2018Paper

Moving Towards a Cure for MS: Increased Immunosuppression and Striving for No Evidence of Disease Activity (NEDA)

Rhode Island Medical Journal
Brian WongSyed Rizvi

Abstract

Multiple sclerosis (MS) is a chronic central nervous system demyelinating disease. The cause is unknown, but likely results from a combination of genetic predisposition and environmental exposures leading to autoimmune destruction of the brain and spinal cord. The most common phenotype of MS is relapsing-remitting (RRMS), characterized by episodes of neurological symptoms, typically lasting days to weeks, followed by symptom remission. After years of disease, the majority of RRMS cases transform into secondary progressive MS (SPMS), characterized by slowly worsening symptoms and progressive neurological disability, which may or may not be also accompanied by superimposed relapses. A third distinct phenotype, primary progressive MS (PPMS) is characterized by slowly worsening neurological symptoms and disability from disease onset, without clinical relapses.1 The first disease-modifying agent was approved by the FDA in 1993. There are now 14 FDA-approved disease-modifying therapies (DMTs) with almost all agents indicated for relapsing forms of MS. The medical management of multiple sclerosis has changed dramatically over the past decade as the number of available DMTs has increased (See Table 1). Most of the newer agents have bee...Continue Reading

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

CNS & Neurological Disorders Drug Targets
Omer Anlar
Expert Opinion on Emerging Drugs
Claudio GasperiniCarlo Pozzilli
© 2022 Meta ULC. All rights reserved